Arcus Biosciences Inc(RCUS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:07 AM ET (Korea 10/28 17:07)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.9 | Insider Own | 32.85% | Shs Outstand | 127.0M | Perf Week | -23.62% |
| Market Cap | 2.31B | Forward P/E | - | EPS next Y | 7.25% | Insider Trans | -0.27% | Shs Float | 85.5M | Perf Month | -27.47% |
| Enterprise Value | 1.72B | PEG | - | EPS next Q | -0.89 | Inst Own | 68.71% | Short Float | 14.45% | Perf Quarter | -31.42% |
| Income | -0.46B | P/S | 19.74 | EPS this Y | -8.29% | Inst Trans | 2.94% | Short Ratio | 7.07 | Perf Half Y | -26.85% |
| Sales | 0.12B | P/B | 4.97 | EPS next 5Y | 8.31% | ROA | -46.02% | Short Interest | 12.36M | Perf YTD | -23.88% |
| Book/sh | 3.65 | P/C | 3.29 | EPS past 3/5Y | 3.94% -7.95% | ROE | -90.82% | 52W High | -42.84% ($31.74) | Perf Year | -2.47% |
| Cash/sh | 5.51 | P/FCF | - | Sales past 3/5Y | 30.16% 26.08% | ROIC | -81.42% | 52W Low | 4.07% ($17.43) | Perf 3Y | 26.59% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -23.18% | Gross Margin | 92.31% | Volatility(W/M) | 11.04% 6.96% | Perf 5Y | -45.18% |
| Dividend TTM | - | EV/Sales | 14.72 | Sales Y/Y TTM | -55.34% | Oper. Margin | -415.38% | ATR (14) | 1.57 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.82 | EPS Q/Q | - | Profit Margin | -393.16% | RSI (14) | 28.19 | Recom | 1.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.82 | Sales Q/Q | -74.38% | SMA20 | -19.45% ($22.52) | Beta | 1.01 | Target Price | $41 |
| Payout | - | Debt/Eq | 0.25 | Earnings | 2026/11/4 | SMA50 | -29.31% ($25.66) | Rel Volume | 1.28 | Prev Close | $17.76 |
| Employees | 601 | LT Debt/Eq | 0.22 | EPS/Sales Surpr. | 19.21% 86.52% | SMA200 | -26.65% ($24.73) | Avg Volume(3M) | 1.75M | Price | $18.14 |
| IPO | 2018/3/15 | Option/Short | Yes/Yes | Trades | 16875 | Volume | 2,231,859 | Change | 2.14% |
A clinical-stage biotech company developing immuno-oncology treatments. It focuses on immune-based and targeted cancer therapies and has attracted attention through partnerships with major pharmaceutical companies and progress in its clinical programs. The company is a biotech firm specialized in immuno-oncology treatments.
Over the past 1 year, on the lower side
43% below its 1-year high.
Traded more than usual. That is 128% of its average volume.
Next earnings report: November 4
7 days to go.
RCUS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -8.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,974. Peers typically go for $1,648. Compared with its own 1-year average, it is 35% cheaper now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -45.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 68.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #86 of 594 in the industry
Based on market cap of $2B.
FTRE#85 Fortrea Holdings Inc $2B PER - RCUS#86 Arcus Biosciences Inc $2B PER - 
BHVN#87 Biohaven Ltd $2B PER - 
AUPH#88 Aurinia Pharmaceuticals Inc $2B PER 7.5 
AGIO#89 Agios Pharmaceuticals Inc $2B PER - 
FAQ
What kind of company is RCUS?
RCUS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RCUS?
The market cap of RCUS is approximately $2.3B, ranking 1,947 within its sector.
What is the 52-week high and low for RCUS?
RCUS has recorded a 52-week high of $31.74 and a low of $17.43.
